增长差异化因子-15与与拥堵相关的厌食症和晚期心力衰竭中体重减轻有关
Luca Monzo1, Petr Jarolim2, Barry A Borlaug3
1Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic; Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France.
JACC. Heart failure
|January 11, 2025
概括
高增长差异化因子 (GDF) -15在晚期心力衰竭中与减少喷射率 (HFrEF) 相对应于厌食症,缓冲症和更糟糕的结果. 这种细胞因子可能表明死亡风险增加或需要先进疗法.
科学领域:
- 心脏病学 心脏病学
- 代谢综合征是代谢综合征的一种.
- 细胞因子信号传递
背景情况:
- 增长差异化因子 (GDF) -15是一种细胞因子,与癌症患者的食欲抑制和体重减轻有关.
- 它在心力衰竭中的作用,特别是在心力衰竭的先进阶段,需要进一步阐明.
研究的目的:
- 为了研究GDF-15水平与厌食症,黄昏症和高级HFrEF患者的临床结果之间的关联.
- 探索GDF-15与代谢障碍和心脏功能的关系.
主要方法:
- 对344名晚期HFrEF患者进行了观察后期分析.
- 评估包括临床和心声学评估,身体成分分析,代谢物概况和右心导管检查.
主要成果:
- 较高的GDF-15水平与厌食症,黄昏症和代谢性代谢状态的增加有关 (增加的自由脂肪酸,β-基酸;减少的白蛋白,胆固醇,胰岛素/葡萄糖比率).
- 升高的GDF-15也与更大的拥堵和右心室功能障碍相关.
- GDF-15独立预测了死亡,紧急移植或左心室辅助装置植入的复合终点.
结论:
- 在先进的HFrEF中,高GDF-15与厌食症,黄昏症,心脏功能障碍和拥堵有关.
- 循环GDF-15是这个患者群体中不良临床事件的独立预测因素.
- 对GDF-15向疗法的进一步研究是有必要的,以改善代谢状态和结果.
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Role of Hematopoietic Growth Factors
1.2K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.2K
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Anorexia Nervosa
43
Anorexia nervosa is a complex and severe eating disorder characterized by an intense fear of weight gain, an unrelenting pursuit of thinness, and a distorted body image. It often leads to dangerously low body weight relative to an individual's age and height. This disorder is marked by significant physical and psychological consequences, making it one of the most life-threatening psychiatric illnesses.
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
43
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Heart Failure Drugs: Inotropic Agents
515
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
515


